Latest News

Bacthera Announces Corporate Restructuring and Manufacturing Reprioritization

  • Bacthera will decommission sites in Hørsholm (DK), León (ES) and Basel (CH) to focus activities on commercial live biotherapeutics manufacturing.
  • Phased closure assumed to commence in Q3 2024 and assumed to be completed by mid-2025.
  • There are continuing discussions with Nestlé Health Science regarding the ramp-up of the Bacthera Visp facility for the commercial manufacture of VOWST.

Basel, Switzerland, León, Spain and Hørsholm, Denmark, 26 June 2024 —Bacthera, a specialized contract development and manufacturing organization (CDMO), announced today that it will decommission its development and manufacturing facilities in Hørsholm (DK), León (ES) and Basel (CH). This is designed to support a streamlined set of priorities in a challenging commercial environment.

In Visp, Bacthera is currently focusing exclusively on its ramp-up for the commercial manufacture of VOWST, an FDA-approved treatment for recurrent Clostridioides difficile infection (rCDI). Discussions are continuing with Nestlé Health Science (the announced future global rights owner of VOWST) about whether or not the ramp-up will continue.

The phased site closures are expected to begin in Q3 2024 in Hørsholm (DK), followed by León (ES) and Basel (CH) and expected to be complete by mid-2025.

Bacthera will work with business partners and customers to define the best way forward for signed and scheduled projects and remains committed to its employees during this restructuring.